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http://dx.doi.org/10.1016/j.pedneo.2Background: Severe pulmonary hemorrhage is a serious complication with a high mortality rate
in preterm infants with respiratory distress syndrome (RDS) after surfactant therapy. The aim
of this study is to evaluate the efficacy of our current management strategy for neonates with
severe pulmonary hemorrhage.
Materials and methods: Very-low-birth-weight (VLBW) infants who developed severe pulmo-
nary hemorrhage were studied from January 2006 to August 2011. Treatment for severe pulmo-
nary hemorrhage in our neonatal intensive care unit (NICU) included intratracheal epinephrine
spraying/irrigation, blood component therapy, and as necessary, surfactant supplement ther-
apy was administered in cases that secondary RDS was diagnosed. High frequency oscillatory
ventilation (HFOV) was utilized when hypoxia or respiratory acidosis persisted under conven-
tional mechanical ventilation (CMV). We then described the clinical courses of severe pulmo-
nary hemorrhage following our management.
Results: A total of 18 (3.2%) out of 469 VLBW infants developed severe pulmonary hemorrhage.
The mean gestational age was 27 weeks, the mean birth weight was 822 g, and the onset age
was 2.5 days after birth. There was no severe pulmonary hemorrhage-associated mortality dur-
ing this period with the exception of one case, in which an infant died after the parents
refused to do further therapy. Sixteen (88.8%) neonates had RDS and 13 received surfactant
therapy. Twelve (66.6%) cases developed secondary RDS following the onset of severe pulmo-
nary hemorrhage, and four cases received surfactant supplement therapy. In the surfactant
supplement group, alveolar-arterial oxygen difference (AaDO2) and oxygenation index (OI) dur-
ing the 2e4 hours postpulmonary hemorrhage period showed statistically significantof Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine,
aipei 100, Taiwan.
w (P.-N. Tsao).
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Pulmonary hemorrhage in preterm infants 331improvement, whereas the other group only showed a tendency toward improvement without
reaching statistical significance when compared to the baseline data. Duration of high oxygen
requirement [defined as fraction of inspired oxygen (FiO2) > 40%] was also less in the surfac-
tant supplement group.
Conclusion: This data suggests that our current strategy is effective for treating severe pulmo-
nary hemorrhage in VLBW infants. Surfactant therapy for severe pulmonary hemorrhage may
also be beneficial for improving lung function and may shorten the duration of high oxygen
requirement.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Pulmonary hemorrhage occurs mainly in ventilated preterm
infants with severe respiratory distress syndrome (RDS), who
have received surfactant therapy. The incidence of pulmo-
nary hemorrhagewas around 0.5e11% among a population of
very-low-birth-weight (VLBW) infants.1e6 Pulmonary hem-
orrhage is associated with significant morbidity and mortal-
ity, and the mortality rate is high, ranging from 50% to
82%.7e10 Risk factors for pulmonary hemorrhage included
prematurity, intrauterine growth restriction, respiratory
problems, patent ductus arteriosus (PDA), bleeding prob-
lems, ventilator usage, and surfactant treatment.4,11,12
Pulmonary hemorrhage was thought to be a complica-
tion of surfactant therapy. Thus, clinicians might hesitate
to administer surfactant again in neonates presenting with
pulmonary hemorrhage. However, the presence of hemo-
globin, red cell membrane lipids, and serum proteins can
increase the surface tension resulting from surfactant
dysfunction and cause secondary RDS.13
The purpose of this study is to analyze the incidence and
short-term outcome of severe pulmonary hemorrhage in
VLBW infants following our current treatment, including
intratracheal epinephrine spraying/irrigation; blood
component therapy; and in some cases, surfactant sup-
plement in our NICU from January 2006 to August 2011.2. Materials and Methods
2.1. Patients
This 5-year retrospective study was conducted in the
neonatal intensive care unit at National Taiwan University
Hospital between 2006 and 2011. All infants weighing
<1500 g and who had developed severe pulmonary hem-
orrhage were eligible for the study. The definition of severe
pulmonary hemorrhage was based on previously established
criteria; namely the presence of blood-stained aspirates
from endotracheal tube (ET) with either of the followings:
multilobular infiltrates on chest radiograph, increased
ventilation support (fraction of inspired oxygen (FiO2) in-
crease of >0.3 from the baseline), or acute drop of hem-
atocirt (>10%).8 Secondary RDS was defined as deteriorated
respiratory symptoms in clinical course and white-out
pattern from the chest radiograph.2.2. Management protocol
All cases received 0.5 cc epinephrine (1:10000) spraying/
irrigation via ET each time after ET suction until pulmonary
hemorrhage was resolved. Patients with severe pulmonary
hemorrhage received ET suction only when they had dys-
pnea, hypercapnea, or hypoxemia. The epinephrine spray-
ing was conducted as fast as possible to create a splash via a
force injection of a mixture of 0.5 cc diluted epinephrine
with 1 cc air in a 5 cc syringe connected to an oral-gastric
tube. If respiratory failure was reflected as FiO2 > 60% with
a mean airway pressure (MAP) > 12 cm H2O, and/or per-
sisted respiratory acidosis (pH < 7.25) in spite of conven-
tional mechanical ventilator (CMV) support, we switched
out the ventilator to a high frequency oscillation ventilator
[HFOV; SensoreMedics model 3100 (Critical Care Corp.,
Yorda Linda, CA, USA)] to avoid barotrauma while main-
taining optimal lung volume. Ventilator setting, arterial
blood gases, oxygenation index (OI), and alveolar-arterial
oxygen difference (AaDO2) were recorded at specific
intervals for at least 8 hours. The decision to administer
surfactant following the pulmonary hemorrhage-induced
RDS was made by each attending neonatologist. Blood
component therapy was given if coagulopathy or thrombo-
cytopenia was evident.
2.3. Outcomes
Resolution of pulmonary hemorrhage in our cases was
defined as cessation of fresh blood aspirate from the ET and
achieving clinical stabilization by decreasing oxygen de-
mand and ventilator setting. The outcome was a change in
respiratory status following therapy as reflected by change
in OI, AaDO2, and the duration of high oxygen requirement
(defined as time to wean FiO2 < 40%) between different
therapy groups. Statistical analysis was performed using the
student t test. A p value < 0.05 was considered statistically
significant.3. Results
A total of 469 VLBW preterm neonates were admitted to our
NICU during this period, of which 26 (5.5%) cases developed
pulmonary hemorrhage; however, only 18 (3.8%) patients
fulfilled the criteria of severe pulmonary hemorrhage. The
Table 1 Characteristics of patients with severe pulmo-
nary hemorrhage.
Characteristics Patients with
severe pulmonary
hemorrhage
(n Z 18)
Birth weight (g) 820  246
Gestational age (wk) 27  2
Sex M/F 9/9
Age (d) 2.4  1.3
RDS requiring surfactant therapy 13/18 (72.2)
Hemorrhage onset within
72 h of surfactant
13/13 (100)
Epinephrine use (irrigation/spraying) 18/18 (100)
HFOV use 14/17 (82.3)
Pulmonary hemorrhage-related RDS 12/17 (70.5)
Secondary surfactant therapy
for severe pulmonary hemorrhage
4/12 (33.3)
OI prior to hemorrhage 8  1
AaDO2 prior to hemorrhage 146  95
Death due to severe pulmonary
hemorrhage
1/18 (5.5)*
Survived to discharge 13/18 (72.2)
Data are presented as n (%) or mean  SD unless otherwise
indicated. OI: [(FiO2  Mean Airway Pressure)/PaO2]  100,
AaDO2: [(713  FiO2)  (PaCO2/0.8)]  PaO2.
* One patient died after his parents refused further therapy.
AaDO2 Z alveolar-arterial oxygen difference; HFOV Z high
frequency oscillatory ventilation; OI Z oxygenation index;
RDS Z respiratory distress syndrome.
Table 2 Characteristics of patients who developed sec-
ond RDS following severe pulmonary hemorrhage.
Surfactant
group (n Z 4)
Without surfactant
group (n Z 8)
p*
Gestational
age (wk)
27  1.4 27.1  1.45 0.93
Birth weight 902.5  2521.7 858.6  252.9 0.74
Sex (M/F) 3/1 5/3
Values at hemorrhage
MAP 15.0  2.2 12.3  3.3 0.19
FiO2 1  0 0.9  0.1 0.26
pH 7.13  0.17 7.14  0.16 0.85
PaCO2 66.4  54.3 60.7  15.9 0.35
OI 37.8  9.3 29  19.7 0.45
AaDO2 563.6  122.2 535.7  71.6 0.35
Data are presented as mean  standard deviation.
AaDO2 Z alveolar-arterial oxygen difference;
FiO2 Z fractionated inspired oxygen; MAP Z mean airway
pressure; OI Z oxygenation index; PaCO2 Z partial arterial
carbon dioxide; RDS Z respiratory distress syndrome.
* unpaired two-tailed t test, and p < 0.05 is considered
significant.
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patients were 27  2 weeks and 820  246 g, respectively.
Among the 18 VLBW neonates with severe pulmonary
hemorrhage, 16 (88.9%) patients had RDS and 13 required
surfactant therapy. PDA was documented by cardiac echog-
raphy in 8 patients (44.4%). Among the 13 cases with RDS
requiring surfactant therapy, severe pulmonary hemorrhage
always appearedwithin 72 hours after surfactant treatment.
There were 5 patients who did not survive to the discharge,
and one was associated with severe pulmonary hemorrhage
for which his parents refused further therapy, and this case
was excluded from the following analysis. The other four
patients survived from pulmonary hemorrhage but later died
from other causes: One patient developed pneumothorax
and pneumopericardium incidentally and died 3 days later
following the resolution of pulmonary hemorrhage. Two pa-
tients had refractory hypotension: in one patient, it was
caused by cardiac tamponade at the age of 44 days, and the
other one developed severe intraventricular hemorrhage,
complicated with hyperkalemia at 3 days of age. One infant
died at 1 month of age from systemic fungal infection. The
majority of pulmonary hemorrhage caseswere resolved after
3e5 treatments of epinephrine spraying, even when the
neonates were still under a high setting of ventilation sup-
port. Twelve (70.5%) of the 17 patients developed secondary
RDS because of surfactant dysfunction, and four of them
received an additional dose of surfactant therapy. HFOV was
utilized in 14 neonates (Table 1).
To analyze the effect of surfactant therapy for those
infants with severe pulmonary hemorrhage-induced sec-
ondary RDS, we compared the blood gases, OI, and AaDO2
between treatment with and without the surfactant group.
The basic profile of both groups (gestational age and birth
weight), initial values of blood gases, OI, and AaDO2 after
severe pulmonary hemorrhage induced RDS were not
significantly different between these two groups. However,
the average values of OI and AaDO2 were higher in the
surfactant treatment group (Table 2).
The average time of surfactant therapy was 1.2 hours
following the development of severe pulmonary hemor-
rhage, with a range of 0.5 hour to 1.5 hours. In the sur-
factant treatment group, there was a statistically
significant improvement in AaDO2 (p Z 0.029) and OI,
(pZ 0.012) when comparing the values between the initial
posthemorrhage period (0e1 hour) and the 2- to 4-hour
posthemorrhage period, while whereas the group without
surfactant treatment only showed a tendency toward
improvement (AaDO2, p Z 0.457; OI, p Z 0.606; Table 3).
In addition, half (4/8) of the neonates without surfactant
treatment therapy had increased OI in the second hour
compared with the first hour after the onset of severe
pulmonary hemorrhage (data not shown). By contrast, all
neonates in the surfactant treatment groups had substan-
tially decreased OI in the second hour following the onset of
severe pulmonary hemorrhage when compared to the first
postpulmonary hemorrhage hour. In the surfactant treat-
ment group, the duration to wean FiO2 < 40% after pul-
monary hemorrhage was also shorter compared to the other
group (p Z 0.05).
After the development of severe pulmonary hemorrhage,
HFOV was provided to 12 patients who originally used CMV.
HFOV worked well in all cases even though pulmonaryhemorrhage is not a good indication for HFOV therapy. The OI
and AaO2 both decreased dramatically during HFOV support.
All patients survived from severe pulmonary hemorrhage
without HFOV-related complications.
Table 3 Values following severe pulmonary hemorrhage-induced RDS among neonates with (n Z 4) and without surfactant
therapy (n Z 8).
With surfactant Without surfactant
AaDO2 OI AaDO2 OI
0e1 h 563.6  122.2 37.8  9.3 524.5  71.4 27.5  21.1
1e2 h 465.4  131.0 28.6  17.0 488.6  114.8 26.5  14.8
2e4 h 334.7  144.4* 16.7  7.4* 471.2  136.2 20.6  14.9
Time taken to reach FiO2 < 40% (h) 13.4 (11e16)
y 41.1 (8e108)y
AaDO2 Z alveolar-arterial oxygen difference; OI Z oxygenation index; RDS Z respiratory distress syndrome.
* Compared to 0e1 hour data, paired two-tailed t test, and p < 0.05 is considered significant.
y Two groups comparison, unpaired two-tailed t test, and p Z 0.05.
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In this study,we demonstrated a good short-term outcome of
severe pulmonary hemorrhage in VLBW infants using our
current treatment policy. Our policy for managing severe
pulmonary hemorrhage included stopping pulmonary hem-
orrhage by epinephrine spraying through an ET, thereby
avoiding unnecessary endotracheal suction, and treating
secondary RDS by HFOV with and without surfactant. Our
data showed that active pulmonary hemorrhage usually
stopped after 3e5 instances of epinephrine spraying. This
suggests that using epinephrine spraying through an ET is an
effective therapy to treat pulmonary hemorrhage.14 We
replaced conventional mechanical ventilation with HFOV in
14 out of the 18 patients as a result of hypoxemia and/or
persistent respiratory acidosis. Generally, HFOV is consid-
ered less effective in an obstructive lung condition like a
pulmonary hemorrhage, and few preliminary studies aimed
at analyzing the effect of HFOV in respiratory distress sec-
ondary to pulmonary hemorrhage in VLBW infants have been
conducted.15e17 Ko et al16 reported that 13 (72%) of 18 of
their patients responded to HFOV and survived, and their OI
decreased significantly at 1 hour after HFOV therapy.16
Alkharfy et al achieved a 59% of survival rate (10/17), and
OI improved significantly at 3 hours after HFOV therapy.17 In
our study, none of the patients diedwithin 24 hours of severe
pulmonary hemorrhage under HFOV therapy. Similarly, the
FiO2, OI, and AaDO2 decreased significantly after HFOV use
for 1 hour. These data suggest that HFOV could be used as an
alternative ventilator therapy in cases where CMV fails to
support VLBW infants with severe pulmonary hemorrhage.
Pulmonary hemorrhage appears to be a complication of
surfactant therapy. Increased risk of pulmonary hemor-
rhage has been reported following surfactant therapy
either as prophylaxis or treatment of RDS.4,18 Improved lung
compliance after surfactant therapy with a left-to-right
shunt at ductus arteriosus may contribute to pulmonary
hemorrhage. Surfactant therapy has also been demon-
strated to cause in vitro cytotoxicity, leading to impaired
membrane integrity at the level of the alveolar capillary.19
The presence of hemoglobin, red cell membrane lipids,
and serum protein increased surface tension and inactivated
the surfactant, resulting in secondary RDS.13 Therefore,
there was a rationale for the use of surfactant in pulmonary
hemorrhage induced RDS.9,20,21 In our retrospective case
series, 13 neonates (72.2%) developed secondary RDSfollowing the onset of severe pulmonary hemorrhage. This
indicates that secondary RDS after severe pulmonary hem-
orrhage is common in VLBW infants and should also be
treated properly. As posited by Amizuka et al, lower birth
weight and lower gestational age are significantly associated
with having a good response to exogenous surfactant after
pulmonary hemorrhage.20 A shorter interval between the
onset of pulmonary hemorrhage and surfactant administra-
tion showed an immediate response to the surfactant, fol-
lowed by no increase in ventilator index. In our study, the
average timeof surfactant administrationwas 1.2 hours after
the development of severe pulmonary hemorrhage and
improvement of OI and AaDO2 was most significant at 2e4
hours posthemorrhage in the surfactant group. No patients
deteriorated or experienced a recurrent pulmonary hemor-
rhage following surfactant administration. In another study
by Pandit et al, OI and a/A ratio showed significant
improvement during the 3- to 6-hour postsurfactant period.
Although no formal recommendation based on randomized
study can be presented to evaluate the effect of surfactant
therapy in pulmonary hemorrhage,22 our data and previous
reports suggest that surfactant therapymay be beneficial for
cases with severe pulmonary hemorrhage.9,10,20,21
In conclusion, treatments including epinephrine spraying
through an ET, avoiding unnecessary endotracheal suction,
blood component therapy, HFOV support, and surfactant
therapy (in the case of secondary RDS) were found to be
safe and effective for VLBW infants who developed severe
pulmonary hemorrhage.
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